Pharmaceutical manufacturing networks are undergoing rapid restructuring to expand fill-finish capacities for GLP-1 receptor agonists. The unprecedented volume demand has created localized shortages and pressured competitive drug development categories.
Capital Expenditure Realignment
Contract development and manufacturing organizations (CDMOs) are directing over 30% of active capital projects toward sterile injectable infrastructure. Payers are simultaneously re-evaluating long-term cardiovascular coverage frameworks to accommodate recurring treatment costs.